N/A N=798 Communicating Risk Information for Obesity
Obesity
Primary: Intentions to Lose Weight - Effect of Study Arm on Outcomes — 3.06; 3.37; 3.26; 3.26 units on a scale — p=.0150
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=39 Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale
N/A N=601 Genetic Testing for Type 2 Diabetes
Diabetes Mellitus
Primary: Weight — 103.8; 100.7 kg — p=0.44
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
N/A N=47 Antecedents of Obesity: Fetal Measures of Adiposity
Obesity
Primary: Infant Adiposity at 24-72 Hours Following Birth — 11 Percentage of total body weight
N/A N=24 Growth Hormone as a Determinant of Weight Regulation
Obesity
Primary: 24 Hour Average Plasma Growth Hormone Concentration — 0.4; 1.2; 4.1 ng/mL
Phase 3 N=193 Individualized Obesity Pharmacotherapy
Obesity
Primary: Change in Total Body Weight — -7.7; -6.5 percent change
N/A N=145 The Personalized Nutrition Study
Weight Loss
Primary: Weight Change — -5.5; -4.1; -5.3; -5.1 kg
N/A N=10 Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Change in Weight — -.5 kg — p=.07
N/A N=40 Fat Perception in Humans (09-0873)
Obesity
Primary: Oleic Acid Detection Level — -0.3; -1.2; -1.0 log10 (%W/V OLEIC ACID) — p=0.05
N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL
N/A N=26 Fatty Acid Oxidation Disorders & Body Weight Regulation Grant
Trifunctional Protein Deficiency
Primary: An Outcome of This Study is the Difference in Percent Body Fat (%BF) Between Subjects With a Long-chain Fatty Acid Oxidation Disorder and Normal Controls. — 31.8; 27.2…
N/A N=27 Erythrocyte and Adipocyte G6PD Activity Levels in Obesity
Diabetes · Obesity
Primary: Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. — 3.12; 0.67; 22; 13 nM/min/mg — p=<0.05
Phase 2 N=213 Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Genetic Obesity · Obesity · Obesity Due to Melanocortin 4 Receptor Deficiency
Primary: Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment — 6; 3; 7; 7 Participants
Phase 3 N=12 Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Bardet-Biedl Syndrome · POMC Deficiency Obesity · PCSK1 Deficiency Obesity
Primary: Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52 — 85.7; 80.0 percentage of participants
N/A N=22 Regulation of Muscle Protein Phenotype in Humans With Obesity
Obesity
Primary: Whole-Muscle Protein Synthesis — 0.004; 0.015 %/hr
N/A N=281 Maternal-Offspring Metabolics:Family Intervention Trial
Pregnancy · Weight Gain
Primary: Gestational Weight Gain (GWG) — 12; 10 kg — p=0.01
N/A N=50 Bariatric Surgery for Morbid Obesity
Obesity · Morbid Obesity
Primary: Size of Adipocytes — 73.4; 99.0; 103.0 µm
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
N/A N=20 Protection Against Insulin Resistance in Obesity
Obesity · Insulin Resistance
Primary: Insulin Sensitivity — 273; 817 nmol/kg FFM/min /(µU/mL Insulin)
N/A N=41 Fatty Acid Oxidation Defects and Insulin Sensitivity
Very Long-chain Acyl-CoA Dehydrogenase Deficiency · Trifunctional Protein Deficiency · Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
Primary: Glucose Disposal Rate (Rd)- the Rate of Glucose Infusion to Maintain Euglycemia During Steady State Insulin Infusion in mg/Min — 709; 429; 842; 497 mg/min — p=0.136
Phase 3 N=98 Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Asthma · Obesity
Primary: Asthma Control Questionnaire (Juniper) — 1.13; 1.08; -0.08; -0.09 score on a scale — p=0.05
N/A N=38 Mechanisms of Obesity and Its Metabolic Complications in Youth
Obesity, Childhood
Primary: Rate of Appearance of Acetate — 7.40; 7.69; 9.29; 14.7 umol/kg/min
Phase 4 N=70 Mechanisms Underlying Metabolic Syndrome in Obesity
Metabolic Syndrome · Insulin Resistance · Prediabetes
Primary: Change in Insulin Sensitivity Using FSIGT — 1.7; 2.4; 7.02 FSIGT units (x10^-4/min/uU/ml)
N/A N=137 Beige Fat, Energy, and the Natriuretic Peptide System
Obesity
Primary: Adipose Tissue Gene Expression of UCP1 (Uncoupling Protein 1)- Differences by Obesity Status — 7.79; 24.33 fold change — p=<0.01
N/A N=67 Obesity Risk in African American Women is Determined by a Diet-by-phenotype Interaction
Diet Modification
Primary: Total Energy Expenditure — 2411; 2316; 2318; 2179 kcal/day
N/A N=16 Characterization of Bile Acid Pathway in Obesity
Obesity
Primary: Change in 48h-fecal Bile Acid Excretion (μmol/L) Between Baseline and High Fat Diet — 543; 344 (μmol/L)/48 hour
N/A N=15 Genetic-specific Effects of Fructose on Liver Lipogenesis
NAFLD
Primary: Mean Change in Liver Fat Content Based on Elastography — -0.15; 1.10 kilopascal (kPa) — p=0.40
N/A N=28 Dopamine and Insulin Resistance
Obesity
Primary: Striatal DRD2 Receptor Binding — 28; 33; 32; 33 ratio — p=<0.05
N/A N=5 Sympathetic Activation in Obesity
Obesity · Healthy
Primary: Distribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System — 0.13; -0.025; 0.095; -0.03 DVR